Latest News

The Middle Eastern stock markets have recently shown positive momentum, driven by encouraging developments in US-Iran diplomatic talks and record highs in Egypt's indices. Amidst this backdrop, the concept of penny stocks continues to hold relevance as these smaller or newer companies can present unique investment opportunities when they possess strong financial foundations. In this article, we will explore three noteworthy penny stocks from the region that stand out for their financial...

As the Middle East markets experience a positive shift, buoyed by upbeat US-Iran talks and record highs in Egypt's indices, investors are increasingly optimistic about the region's economic prospects. In this environment, identifying stocks with strong fundamentals and growth potential becomes crucial for those looking to capitalize on emerging opportunities.

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

GP ECO Solutions India (NSE:GPECO) has had a rough three months with its share price down 24%. But if you pay close...

Market context and recent performance Corvus Pharmaceuticals (CRVS) has drawn investor attention after a sharp share price move, with the stock up 7.35% in the latest session and posting significant gains over the past month. See our latest analysis for Corvus Pharmaceuticals. The latest move sits within a very strong run, with a 30 day share price return of 201.33% and year to date share price return of 179.51%. The 1 year total shareholder return of 306.76% and very large 3 year total...

UGI (UGI) is back in focus after reporting first quarter results that included a 5% year over year EBIT increase, the completion of its LPG portfolio rationalization, and a Moody’s outlook upgrade for AmeriGas. See our latest analysis for UGI. Despite the recent EBIT progress and LPG portfolio clean up, UGI’s share price has been under some pressure in the short term, with a 1 day share price return of a 2% decline and a 7 day share price return of a 7.6% decline, while the 90 day share price...

Why lucerastat’s new Phase 3 plan matters for Idorsia shareholders Idorsia (SWX:IDIA) has agreed with the US FDA on a Phase 3 registration program for lucerastat in Fabry disease, centered on kidney outcomes and backed by recently published MODIFY trial data. For you as an investor, this means lucerastat is moving from exploratory late stage data into a clearly defined path that is intended to support a potential marketing application, with health authority alignment already in place. See our...

Neogen Corporation recently initiated a voluntary recall of all in-date lots of its Vet HYCOAT Hyaluronate Sodium Sterile Solution for animals, after microbial contamination was detected in certain 10 mL/50 mg vials and adverse events were reported in horses when used off-label as intraarticular injections. Although no adverse events have been reported when HYCOAT is used as labeled for topical wound management, the company has extended the recall to additional lot sizes and is working with...

Konecranes (HLSE:KCR) has just combined a proposed €2.25 per share dividend, fresh 2026 guidance and solid 2025 results, giving investors new information on cash returns, earnings power and order momentum in eco efficient equipment. See our latest analysis for Konecranes. The recent dividend proposal and steady 2026 guidance come after a mixed stretch in the share price, with a 7 day share price return of a 10.44% decline but a 90 day share price return of 8.04%, while the 1 year total...

Why Aurubis stock is back on investors’ radar Aurubis (XTRA:NDA) has drawn fresh attention after raising its 2025–26 operating EBT guidance to €375 million to €475 million. This follows a first quarter with higher sales and net income versus a year earlier. See our latest analysis for Aurubis. The raised guidance and strong first quarter have coincided with a sharp move in the stock, with a 30.35% year to date share price return and a 102.07% total shareholder return over the past year...

Essity’s New EIB Loan and Why It Matters for Shareholders Essity (OM:ESSITY B) has secured a €400 million, 7 year loan from the European Investment Bank. The funds are earmarked for research, development, and innovation across all business areas, with a focus on competitiveness and environmental impact. See our latest analysis for Essity. The new EIB loan arrives after a period of steady gains, with Essity’s share price at SEK278.8 and recent upward momentum reflected in its 7 day and 30 day...

Nurix Therapeutics (NRIX) is in focus after reporting full year 2025 earnings that paired revenue of US$83.98 million with a wider net loss of US$264.46 million, alongside a new US$98.8 million shelf registration. See our latest analysis for Nurix Therapeutics. The latest earnings release and shelf registration have arrived after a volatile stretch, with a 31.03% 90 day share price return contrasting with a 12.69% 30 day decline and a 6.44% 1 year total shareholder return fall. This suggests...

What the latest earnings and dividend mean for Evonik Industries (XTRA:EVK) Evonik Industries (XTRA:EVK) reported full year 2025 results with sales of €14,069 million and net income of €634 million, alongside confirming an annual dividend of €1.00 per share payable in June 2026. See our latest analysis for Evonik Industries. The release of full year 2025 results, which showed sales of €14.1b and net income of €634 million, appears to be in focus for investors. The 7 day share price return of...

The Bancorp, Inc. recently reported full-year 2025 results, with net interest income of US$375.51 million, net income of US$228.21 million, and diluted EPS from continuing operations of US$4.92, alongside materially higher fourth-quarter net charge-offs of US$39.21 million versus US$18.81 million a year earlier. At the same time, the company initiated 2026 earnings guidance of US$5.90 EPS, targeted at least US$1.75 EPS for fourth-quarter 2026, and completed a US$149.99 million buyback of...

Alvotech recently reported positive top-line results from a pharmacokinetic study for AVT80, its subcutaneous biosimilar candidate to Entyvio, and also finalized new global patent settlements and commercial entry timelines for its aflibercept biosimilar AVT06. In parallel, Alvotech entered expanded supply and commercialization agreements with Sandoz across Canada, Australia and New Zealand, signalling a broader role as a development and manufacturing partner for multiple biosimilars. We’ll...

Nichirei Corporation recently reported results for the nine months ended December 31, 2025, with sales of ¥537,666 million and net income of ¥21,858 million, both slightly higher than a year earlier. At the same time, Nichirei’s board approved plans for its North American unit InnovAsian Cuisine to inject new capital into a freshly established Delaware subsidiary, signaling an incremental build-out of its overseas food operations. We’ll now examine how this combination of modest earnings...

What Yelp’s Recent Share Performance Tells Investors Yelp (YELP) is drawing attention after a period of weak share performance, with the stock showing negative returns over the past week, month, past 3 months, year, and on a 3 and 5 year basis. See our latest analysis for Yelp. At the latest share price of $24.42, Yelp’s 7 day share price return of a 10.88% decline and year to date share price return of a 19.14% decline sit alongside a 1 year total shareholder return of a 38.43% loss. This...

Crown Castle Inc. reported past fourth-quarter 2025 revenue of US$1,072 million and full-year 2025 revenue of US$4,264 million, alongside a swing from a very large prior-year net loss to net income of US$444 million, while outlining plans to sell its fiber and small cell businesses and cut about 20% of its workforce. An interesting wrinkle for investors is that Crown Castle paired this restructuring with plans to maintain its US$4.25 annual dividend, authorize US$1 billion in share...

Key Insights China Suntien Green Energy's estimated fair value is HK$4.48 based on Dividend Discount Model China...

Key Insights The considerable ownership by retail investors in Infotel indicates that they collectively have a greater...

Most readers would already be aware that Bhadora Industries' (NSE:BHADORA) stock increased significantly by 16% over...

Renaissance Global Limited ( NSE:RGL ) shareholders might be concerned after seeing the share price drop 14% in the...

Eisai Co., Ltd. ( TSE:4523 ) will pay a dividend of ¥80.00 on the 1st of June. This means the annual payment is 3.6% of...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...